From the Paediatric Intensive Care, Leicester Children's Hospital, Leicester, United Kingdom.
Department of Virology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
Pediatr Infect Dis J. 2021 May 1;40(5):e194-e196. doi: 10.1097/INF.0000000000003081.
We describe 2 expremature infants presenting with SARS-CoV-2-related pulmonary disease in their second and fifth week of life needing support with mechanical ventilation. Both infants' initial presentation was with repeated apneas. These cases highlight that SARS-CoV-2 infection could present with apneas and has the potential to progress to more severe pulmonary disease in this high-risk age group of patients. Both patients were treated with remdesivir (RDV). We provide the data of 2 high-risk neonates successfully treated with RDV without observation of any described side effects. A recognition that these high-risk neonates could deteriorate and early multidisciplinary team discussion is the mainstay to the compassionate access to RDV. Our experience led us to develop a guideline on the use of RDV below 12 years of age, with particular focus on infants and young children.
我们描述了 2 例在出生后第 2 周和第 5 周因 SARS-CoV-2 相关肺部疾病而需要机械通气支持的早产儿。这 2 例患儿最初的表现均为反复呼吸暂停。这些病例提示，SARS-CoV-2 感染可能表现为呼吸暂停，并有可能在这一年龄组高危患儿中进展为更严重的肺部疾病。这 2 例患儿均接受了瑞德西韦（RDV）治疗。我们提供了 2 例高危新生儿成功接受 RDV 治疗的数据，未观察到任何描述的副作用。认识到这些高危新生儿可能会恶化，以及早期多学科团队的讨论，是获得 RDV 同情治疗的主要支柱。我们的经验促使我们制定了 12 岁以下儿童使用 RDV 的指南，特别关注婴儿和幼儿。
